An Economic Evaluation of Cabazitaxel Versus a Second Androgen Receptor‑targeted Agent (ARTA) for Patients with Metastatic Castration‑resistant Prostate Cancer Previously Treated with Docetaxel and an ARTA: the United States Payer Perspective

Dr Thomas Hutson reviews recently published data on patient outcomes and estimated healthcare costs associated with use of third-line cabazitaxel versus a second ARTA in patients with metastatic castration-resistant prostate cancer (CRPC).